Keytruda pembrolizunab
Oncology Videos ASCO 2020 Image Bank Lynparza

KEYTRUDA indications1

INDICATION TREATMENT LINE COMBINATION PD-L1 TESTING DISEASE STAGE
1L
1L
non-squamous
1L
squamous
2L
Monotherapy
With pemetrexed + platinum-based chemotherapy
With carboplatin and paclitaxel or nab-paclitaxel
Monotherapy
≥50% TPS
≥1% TPS
Metastatic
Metastatic
Metastatic
Locally advanced or metastatic
1L Monotherapy or with platinum and 5-fluorouracil CPS ≥1 Metastatic or unresectable recurrent
1L With axitinib Advanced
Adjuvant
1L+ 2L
Monotherapy
Monotherapy
Stage III
Advanced (unresectable or metastatic)
1L for cisplatin-ineligible patients
2L
Monotherapy
Monotherapy
CPS ≥10
Locally advanced or metastatic
Locally advanced or metastatic
2L Monotherapy Relapsed or refractory

1L = first-line; 2L = second-line; 5-FU = 5-fluorouracil; CPS = combined positive score; PD-L1 = programmed death ligand 1; TPS = tumour proportion score.

Indication launches2,a

a. Dates of reimbursement in Belgium.2

1L = first-line; 2L = second-line; cHL = classical Hodgkin lymphoma; HNSCC = head and neck squamous cell carcinoma; NSCLC = non-small-cell lung carcinoma.

References

1. SmPC KEYTRUDA 11/19.

2. www.riziv.fgov.be [Accessed 16/01/2020].

Please consult the prescribing information before prescribing.

BE-KEY-00151 Date of last revision: 03/2020